Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML projectClaudia Sargas, Pau Montesinos, Iria Vázquez et al.|Haematologica|2020Cited by 37
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupClaudia Sargas, Rosa Ayala, María José Larráyoz et al.|Blood Cancer Journal|2023Cited by 28
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry StudyRosa Ayala, Pau Montesinos, Gonzalo Carreño‐Tarragona et al.|Cancers|2022Cited by 12
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA StudyBlanca Boluda, Pau Montesinos, Rebeca Rodríguez‐Veiga et al.|Cancers|2025Cited by 2
Conventional PCR Versus Next Generation Sequencing for Diagnosis of <i>FLT3</i>, <i>IDH</i> and <i>NPM1</i> Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema GroupBlanca Boluda, Pau Montesinos, Claudia Sargas et al.|Blood|2022Cited by 1